undamentalytics Newsletter
Sign in

Korsana Biosciences, Inc. cash flow statement

In fiscal 2025, Korsana Biosciences, Inc.'s operations generated −$3.3m of cash; it spent $0 on capital projects, leaving free cash flow of −$3.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−102−72−37−41−21−4−3−4
Depreciation and amortisation32000———
Stock-based pay20151061100
Capital spending72000000
Free cash flow−109−74−37−41−21−4−3−4
Free cash flow after stock pay−129−89−46−47−22−5−4−5
Shares issued———0501—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: KRSA vs MCRBKRSA vs OVIDABSI vs KRSACLGN vs KRSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Korsana Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Korsana Biosciences, Inc.